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Non-selective beta-blockers (NSBB) are routinely and widely used in patients with liver cirrhosis and portal hypertension. For more than 15 years, carvedilol has been investigated as an alternative for propranolol or nadolol [1] . Due to its additional anti-a1-adrenergic activity, carvedilol might be more potent in decreasing portal pressure, but also leads to more pronounced decreases in systemic arterial pressure when compared to conventional NSBB [1] .
For the prevention of first variceal bleeding in patients with medium to large varices, either NSBB or endoscopic band ligation is recommended [2] . Both traditional NSBB (e.g. propranolol, nadolol) and carvedilol are valid first-line treatments. Carvedilol is more effective than traditional NSBB in reducing the hepatic venous pressure gradient (HVPG) [2] . However, trials with a head-to-head comparison of carvedilol and propranolol with clinical endpoints have not been published, although there has been a trial with a surrogate marker [3] .
For preventing recurrent variceal hemorrhage, first-line therapy for all patients is a combination of NSBB (propranolol or nadolol) plus endoscopic variceal ligation [2] .
Also, in the situation of recurrent variceal bleeding, carvedilol has not yet been compared to the current standard of care (traditional NSBB). Therefore, the benefit of carvedilol in this situation remains unclear. Due to its more potent effect on systolic blood pressure, carvedilol might be particularly beneficial in 'early' portal hypertension. Potential detrimental effects on systemic hemodynamics might be less relevant in such patients without advanced cirrhosis. In contrast to that assumption, a recent study found that, overall, carvedilol offered no clear advantage over propranolol in reducing portal pressure. However, in subgroup analysis, carvedilol was more effective in patients with a MELD score above 15 [3] . In this trial, patients were randomized to either the propranolol or the carvedilol group independently of an event or not of bleeding. In contrast in the study [4] published in this issue of Hepatology International (pp. 000-000), only patients with cirrhosis presenting with the first episode of variceal bleeding from June to December 2013 were screened for inclusion criteria. Management comprised somatostatin infusion and cefotaxime. Endoscopic therapy was started in all patients, as follows. In patients with active bleeding, endoscopy was started within 6 h and in the other patients within 24 h. After a 3-to 5-day interval, the hepatic venous pressure gradient was measured and 59 patients were randomized to receive carvedilol or propranolol. HVPG response was defined as a HVPG decrease above 20% or a decrease below 12 mmHg at the second HVPG measurement 4 weeks later. The number of patients with HVPG response was significantly greater in the carvedilol group (75%) than in the propranolol group (50%). In detail, HVPG (mm Hg) at baseline was 17.73 ± 3.07 (carvedilol group) and 17.31 ± 3.02 (propranolol group); HVPG (mm Hg) 4 weeks later decreased to 12.93 ± 3.41 (carvedilol group) and 13.53 ± 3.70 (propranolol group). Therefore, there was no significant difference in the absolute HVPG values between both the groups. There was one episode of rebleeding in each group, occurring on day 7 in the carvedilol group and on day 9 in the propranolol group. The heart rate before treatment in the carvedilol group was 89.06 ± 5.21/min and in the propranolol group 91.06 ± 5.22/min. A dose maximum of 25 mg (achievement of the target heart rate, intolerance or achievement of the maximum allowed total daily dose of 25 mg) was used in the carvedilol group and of 320 mg in the propranolol group. Hereby, heart rate decreased to 62.27 ± 2.81/min and 63.35 ± 3.55/min, respectively. Mean arterial pressure decreased about 11.2 ± 5.17% in the carvedilol group and about 7.8 ± 4.16% in the propranolol group at 4 weeks, which was a significant difference in the percental change between the two groups.
This interesting trial provides data for the direct comparison of traditional NSBB and carvedilol. Such data are most welcome to address the issue whether to use carvedilol or propranolol for the prevention of recurrent bleeding. This study provides interesting data about the differences in the HVPG response to carvedilol versus traditional NSBB even though the absolute values in HVPG showed no difference. The authors suggest using the HVPG response as a surrogate marker to rebleeding risk. But this is also one of the major criticisms of this study, since a surrogate marker rather than one of the suggested endpoints is reported. The endpoints recommended by the Baveno conference [2] for such studies are the development of other complications (e.g. ascites or encephalopathy) after the first bleeding episode or another episode of variceal bleeding. Moreover, the number of patients with ascites (16 patients in the carvedilol group and 21 patients in the propranolol group vs. 14 patients in the carvedilol group and 8 patients in the propranolol group without ascites) was too small in the current study to rule out significant differences. Because the debate about the use of NSBB in patients with ascites is still on-going, such data might be of major interest. Recent data showed a benefit of NSBB for patients on the transplant waiting list and for patients with ACLF [5] , [6] . Propranolol effects may also be due to properties other than reducing portal pressure. Again, it is still important to consider stopping or reducing NSBB (traditional or carvedilol) when one of the following events are occurring: low blood pressure (\90 mm Hg) or serious renal impairment indicated by a relevant increase of serum creatinine. Vice versa presence of ascites per se does not require stopping NSBB, even if ascites is refractory.
In conclusion, the current study by Gupta et al. provides new and interesting data on the effects of carvedilol and propranolol, respectively, for rebleeding prophylaxis. The data suggest a more individualized treatment for patients with portal hypertension. Moreover, the data seem to be a valuable basis to design further studies with generally acknowledged clinical endpoints.
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